References

• 1. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation 2018; 137:109 google scholar
• 2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/ AAPA/ ABC/ ACPM/ AGS/APhA/ ASH/ ASPC/ NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: google scholar
• 3. Bundy JD, Mills KT, Chen J, et al. Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data. JAMA Cardiol 2018; 3 google scholar
• 4. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hy-pertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358:1682 google scholar
• 5. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287:1003 google scholar
• 6. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865 google scholar
• 7. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994; 23:275 google scholar
• 8. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (NICE clinical guideline update). http://www.nice.org.uk (Accessed on January 21, 2009). google scholar
• 9. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-a-ged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37:869 google scholar
• 10. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571 google scholar
• 11. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245 google scholar
• 12. Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021 google scholar
• 13. Young JH, Klag MJ, Muntner P, et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002; 13:2776 google scholar
• 14. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Inter-vention Trial Research Group. Arch Intern Med 1992; 152:56 google scholar
• 15. Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159:2004 google scholar
• 16. Voko Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hyper-tensives. Hypertension 1999; 34:1181 google scholar
• 17. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hy-pertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884 HYPERLINK “https://www.uptodate.com/contents/treatment-of-hypertension-in-older-adults-particularly-isolated-systo-lic-hypertension/abstract/23”-893 google scholar
• 18. Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685 google scholar
• 19. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/ AHA 2011 expert con-sensus document on hypertension in the elderly: a report of the American College of Cardiology foundation task force on clinical expert consensus documents. Developed in collaboration with the American academy of neurology, American geriatrics society, American society for preventive Cardiology, American society of hypertension, American society of nephrology, association of black cardiologists, and European society of hypertension. J Am Coll Cardiol 2011;57:2037-114. google scholar
• 20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older per-sons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265: 3255-64. google scholar
• 21. Perry Jr HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hyper-tension in the Elderly Program (SHEP). J Am Med Assoc 2000;284:465-71. google scholar
• 22. Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. J Am Med Assoc 1997;278:212-6. google scholar
• 23. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64. google scholar
• 24. Liu L, Wang J-G, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16: 1823-9. google scholar
• 25. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72 google scholar
• 26. Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensitymatched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol 2009;103:130-5 google scholar
• 27. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and allcause mortality among older adults taking antihy-pertensive medication. Int J Cardiol 2014;176:219-26. google scholar
• 28. Banach M, Zanchetti A, Bromfield S, Chlebus K, Howard G, Howard VJ, Aronow WS, et al. What is tar-geted diastolic blood pressure in elderly patients-the results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study (abstract). Eur Heart J 2014;35:4799. 2014; (suppl 1): abstract. google scholar
• 29. SPS3 Study Group, Benavente OR, Coffey CS, Conwil R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507-15. google scholar
• 30. Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16. google scholar
• 31. Williamson JD, Supiano MA, Applegate WB, Berkowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years. A randomized clinical trial. J Am Med Assoc 2016;315:2673-82. google scholar
• 32. Whelton K, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 blood pressure trial. JAMA Cardiology 2016;1:855-6. google scholar
• 33. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowe-ring for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. google scholar
• 34. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Bumier M, et al. Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pres 2018; 27:314-40. 2018. google scholar
• 35. Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci 2017;13: 1241-3 google scholar
• 36. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. J Am Med Assoc 2011;305:913-22 google scholar
• 37. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011;29:4-16 google scholar
• 38. Bress AP, Bellows BK, King JB, Beddhu S, Zhang Z, Berlowitz DP, et al. Costeffectiveness of intensive versus Standard blood-pressue cntrol. N Engl J Med 2017;377:745-55. google scholar
• 39. Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: me-ta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. google scholar
• 40. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003;362:591-2. google scholar
• 41. Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9. google scholar
• 42. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hyperten-sion. J Am Coll Cardiol 2015;65:1998-2038. google scholar
• 43. Aronow WS. Current role of beta blockers in the treatment of hypertension. Expet Opin Pharmacother 2010;11:2599-607 google scholar
• 44. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Palensky J, et al. The effect of spironolactone on mor-bidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. google scholar
• 45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowe-ring regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. google scholar
• 46. Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009;2:30. google scholar
• 47. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey Jr DE, et al. ACCF/ AHA/AATS/ACR/ ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. J Am Coll Cardiol 2010;55. e27-e12 google scholar
• 48. Suzuki T, Isselbacher EM, Nienaber CA, Pventz RE, Eagle KA, Tsai TT, et al. Typeselective benefits of me-dications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection (IRAD). Am J Cardiol 2012;109: 122-7. google scholar
• 49. Ernst ME, Carter BL, Geordt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative an-tihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension (Dallas) 2006;47:352-8. google scholar
• 50. Adams M, Bellone JM, Wright BM, Rutecki GW. Evaluation and pharmacologic approach to patients with resistant hypertension. PGM (Postgrad Med) 2012;124: 74-82. google scholar
• 51. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension (Dallas) 2017; 69:411-20. google scholar
• 52. Malik AH, Aronow WS. Efficacy of sacubitril/valsartan in hypertension. Am J Ther 2022 May-Jun;29(3):e322-e333. google scholar
• 53. Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond. Curr Cardiol Rep 2018;20. https://doi.org0.1007/s11886-018-0944-4. google scholar
• 54. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 3 diabetes: the ACCORD randomized trial. Diabe-tes Care 2014;37:1721-8. google scholar
• 55. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, et al. ACC/ AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Developed in collaboration with the American academy of family physicians, the American College of chest physicians, and international society for heart and lung transplantation. J Am Coll Cardiol 2017;70:776-803. google scholar
• 56. Aronow WS.Managing Hypertension in the elderly:What’s new.Am J Prevent Card 2020;1:1-8. google scholar